{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T17:22:35Z","timestamp":1775236955133,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,7]]},"DOI":"10.7759\/cureus.66366","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T11:53:59Z","timestamp":1723031639000},"source":"Crossref","is-referenced-by-count":1,"title":["Secondary Immunodeficiency and Vaccine Response in Rheumatoid and Psoriatic Arthritis on Immunosuppressive Medicines"],"prefix":"10.7759","author":[{"given":"Anthony J","family":"Ocon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiamak","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahzad","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-00816-x","article-title":"The immunology of rheumatoid arthritis","volume":"22","author":"Weyand CM","year":"2021","unstructured":"Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nat Immunol. 2021, 22:10-8. 10.1038\/s41590-020-00816-x","journal-title":"Nat Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00776-6","article-title":"Psoriatic arthritis from a mechanistic perspective","volume":"18","author":"Schett G","year":"2022","unstructured":"Schett G, Rahman P, Ritchlin C, McInnes IB, Elewaut D, Scher JU. Psoriatic arthritis from a mechanistic perspective. Nat Rev Rheumatol. 2022, 18:311-25. 10.1038\/s41584-022-00776-6","journal-title":"Nat Rev Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.31.1.129","article-title":"Infections in patients with rheumatoid arthritis in the era of targeted synthetic therapies","volume":"31","author":"Thomas K","year":"2020","unstructured":"Thomas K, Vassilopoulos D. Infections in patients with rheumatoid arthritis in the era of targeted synthetic therapies. Mediterr J Rheumatol. 2020, 31:129-36. 10.31138\/mjr.31.1.129","journal-title":"Mediterr J Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel L","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al.. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021, 73:1108-23. 10.1002\/art.41752","journal-title":"Arthritis Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh JA","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, et al.. Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019, 71:5-32. 10.1002\/art.40726","journal-title":"Arthritis Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-003-0072-z","article-title":"Secondary immune deficiencies associated with biological therapeutics","volume":"3","author":"Lee SJ","year":"2003","unstructured":"Lee SJ, Yedla P, Kavanaugh A. Secondary immune deficiencies associated with biological therapeutics. Curr Allergy Asthma Rep. 2003, 3:389-95. 10.1007\/s11882-003-0072-z","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217221","article-title":"Reduced IgG titers against pertussis in rheumatoid arthritis: evidence for a citrulline-biased immune response and medication effects","volume":"14","author":"Holmes CL","year":"2019","unstructured":"Holmes CL, Peyton CG, Bier AM, Donlon TZ, Osman F, Bartels CM, Shelef MA. Reduced IgG titers against pertussis in rheumatoid arthritis: evidence for a citrulline-biased immune response and medication effects. PLoS One. 2019, 14:e0217221. 10.1371\/journal.pone.0217221","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei193","article-title":"Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis","volume":"45","author":"Kapetanovic MC","year":"2006","unstructured":"Kapetanovic MC, Saxne T, Sj\u00f6holm A, Truedsson L, J\u00f6nsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006, 45:106-11. 10.1093\/rheumatology\/kei193","journal-title":"Rheumatology (Oxford)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201270","article-title":"Anti-TNF treatment blocks the induction of T cell-dependent humoral responses","volume":"72","author":"Salinas GF","year":"2013","unstructured":"Salinas GF, De Rycke L, Barendregt B, et al.. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis. 2013, 72:1037-43. 10.1136\/annrheumdis-2011-201270","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204427","article-title":"Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)","volume":"74","author":"Bingham CO 3rd","year":"2015","unstructured":"Bingham CO 3rd, Rizzo W, Kivitz A, Hassanali A, Upmanyu R, Klearman M. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2015, 74:818-22. 10.1136\/annrheumdis-2013-204427","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2016.09.003","article-title":"Vaccines and disease-modifying antirheumatic drugs: practical implications for the rheumatologist","volume":"43","author":"Friedman MA","year":"2017","unstructured":"Friedman MA, Winthrop KL. Vaccines and disease-modifying antirheumatic drugs: practical implications for the rheumatologist. Rheum Dis Clin North Am. 2017, 43:1-13. 10.1016\/j.rdc.2016.09.003","journal-title":"Rheum Dis Clin North Am"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1883-1","article-title":"Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy","volume":"21","author":"Winthrop KL","year":"2019","unstructured":"Winthrop KL, Bingham CO 3rd, Komocsar WJ, Bradley J, Issa M, Klar R, Kartman CE. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy. Arthritis Res Ther. 2019, 21:102. 10.1186\/s13075-019-1883-1","journal-title":"Arthritis Res Ther"},{"key":"ref13","article-title":"Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept","volume":"31","author":"Mease PJ","year":"2004","unstructured":"Mease PJ, Ritchlin CT, Martin RW, Gottlieb AB, Baumgartner SW, Burge DJ, Whitmore JB. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol. 2004, 31:1356-61.","journal-title":"J Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00386-12","article-title":"Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study","volume":"19","author":"Chioato A","year":"2012","unstructured":"Chioato A, Noseda E, Stevens M, Gaitatzis N, Kleinschmidt A, Picaud H. Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study. Clin Vaccine Immunol. 2012, 19:1597-602. 10.1128\/CVI.00386-12","journal-title":"Clin Vaccine Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202201381","article-title":"mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients","volume":"5","author":"Azzolini E","year":"2022","unstructured":"Azzolini E, Pozzi C, Germagnoli L, et al.. mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients. Life Sci Alliance. 2022, 5:e202201381. 10.26508\/lsa.202201381","journal-title":"Life Sci Alliance"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00212-5","article-title":"The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study","volume":"3","author":"Mahil SK","year":"2021","unstructured":"Mahil SK, Bechman K, Raharja A, et al.. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol. 2021, 3:e627-37. 10.1016\/S2665-9913(21)00212-5","journal-title":"Lancet Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10010035","article-title":"Reduced humoral response of SARS-CoV-2 antibodies following vaccination in patients with inflammatory rheumatic diseases-an interim report from a Danish prospective cohort study","volume":"10","author":"Schreiber K","year":"2021","unstructured":"Schreiber K, Graversgaard C, Petersen R, et al.. Reduced humoral response of SARS-CoV-2 antibodies following vaccination in patients with inflammatory rheumatic diseases-an interim report from a Danish prospective cohort study. Vaccines (Basel). 2021, 10:35. 10.3390\/vaccines10010035","journal-title":"Vaccines (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.002","article-title":"Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology","volume":"130","author":"Orange JS","year":"2012","unstructured":"Orange JS, Ballow M, Stiehm ER, et al.. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2012, 130:S1-24. 10.1016\/j.jaci.2012.07.002","journal-title":"J Allergy Clin Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2336358","article-title":"State of pneumococcal vaccine immunity","volume":"20","author":"Akkoyunlu M","year":"2024","unstructured":"Akkoyunlu M. State of pneumococcal vaccine immunity. Hum Vaccin Immunother. 2024, 20:2336358. 10.1080\/21645515.2024.2336358","journal-title":"Hum Vaccin Immunother"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3201\/eid2610.191531","article-title":"Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in adults, Japan, 2013-2017","volume":"26","author":"Shimbashi R","year":"2020","unstructured":"Shimbashi R, Suzuki M, Chang B, et al.. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in adults, Japan, 2013-2017. Emerg Infect Dis. 2020, 26:2378-86. 10.3201\/eid2610.191531","journal-title":"Emerg Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.11.065","article-title":"Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults","volume":"25","author":"Singleton RJ","year":"2007","unstructured":"Singleton RJ, Butler JC, Bulkow LR, et al.. Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults. Vaccine. 2007, 25:2288-95. 10.1016\/j.vaccine.2006.11.065","journal-title":"Vaccine"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1165373","article-title":"Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects","volume":"12","author":"Ciprero K","year":"2016","unstructured":"Ciprero K, Zykov KA, Briko NI, et al.. Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects. Hum Vaccin Immunother. 2016, 12:2142-7. 10.1080\/21645515.2016.1165373","journal-title":"Hum Vaccin Immunother"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1011015","article-title":"Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in 2 to 70 year old healthy people in China: a phase III double blind, randomized clinical trial","volume":"11","author":"Li G","year":"2015","unstructured":"Li G, Liang Q, Shi J, et al.. Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in 2 to 70 year old healthy people in China: a phase III double blind, randomized clinical trial. Hum Vaccin Immunother. 2015, 11:699-703. 10.1080\/21645515.2015.1011015","journal-title":"Hum Vaccin Immunother"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.55.4.237","article-title":"Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis","volume":"55","author":"Nakajima A","year":"1996","unstructured":"Nakajima A, Hakoda M, Yamanaka H, Kamatani N, Kashiwazaki S. Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis. Ann Rheum Dis. 1996, 55:237-42. 10.1136\/ard.55.4.237","journal-title":"Ann Rheum Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200637","article-title":"Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study","volume":"71","author":"Heijstek MW","year":"2012","unstructured":"Heijstek MW, van Gageldonk PG, Berbers GA, Wulffraat NM. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study. Ann Rheum Dis. 2012, 71:948-54. 10.1136\/annrheumdis-2011-200637","journal-title":"Ann Rheum Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.01.024","article-title":"Specific antibody deficiencies in clinical practice","volume":"7","author":"Sorensen RU","year":"2019","unstructured":"Sorensen RU, Edgar D. Specific antibody deficiencies in clinical practice. J Allergy Clin Immunol Pract. 2019, 7:801-8. 10.1016\/j.jaip.2019.01.024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease","volume":"80","author":"Haberman RH","year":"2021","unstructured":"Haberman RH, Herati R, Simon D, et al.. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis. 2021, 80:1339-44. 10.1136\/annrheumdis-2021-220597","journal-title":"Ann Rheum Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211128","article-title":"Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"76","author":"Park JK","year":"2017","unstructured":"Park JK, Lee MA, Lee EY, Song YW, Choi Y, Winthrop KL, Lee EB. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2017, 76:1559-65. 10.1136\/annrheumdis-2017-211128","journal-title":"Ann Rheum Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11092418","article-title":"Specific cellular and humoral response after the third dose of anti-SARS-CoV-2 RNA vaccine in patients with immune-mediated rheumatic diseases on immunosuppressive therapy","volume":"11","author":"Mohamed Mohamed K","year":"2023","unstructured":"Mohamed Mohamed K, \u00c1lvarez-Hern\u00e1ndez MP, Jim\u00e9nez Garc\u00eda C, et al.. Specific cellular and humoral response after the third dose of anti-SARS-CoV-2 RNA vaccine in patients with immune-mediated rheumatic diseases on immunosuppressive therapy. Biomedicines. 2023, 11:2418. 10.3390\/biomedicines11092418","journal-title":"Biomedicines"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2022.105380","article-title":"Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: a cohort study and a meta-analysis","volume":"89","author":"Auroux M","year":"2022","unstructured":"Auroux M, Laurent B, Coste B, et al.. Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: a cohort study and a meta-analysis. Joint Bone Spine. 2022, 89:105380. 10.1016\/j.jbspin.2022.105380","journal-title":"Joint Bone Spine"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00992-8","article-title":"Effect of DMARDs on the immunogenicity of vaccines","volume":"19","author":"van Sleen Y","year":"2023","unstructured":"van Sleen Y, van der Geest KS, Huckriede AL, van Baarle D, Brouwer E. Effect of DMARDs on the immunogenicity of vaccines. Nat Rev Rheumatol. 2023, 19:560-75. 10.1038\/s41584-023-00992-8","journal-title":"Nat Rev Rheumatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24984","article-title":"Rheumatoid arthritis disease activity and hospitalized infection in a large US registry","volume":"75","author":"Yun H","year":"2023","unstructured":"Yun H, Chen L, Roy JA, Greenberg J, Harrold LR, George MD, Curtis JR. Rheumatoid arthritis disease activity and hospitalized infection in a large US registry. Arthritis Care Res (Hoboken). 2023, 75:1639-47. 10.1002\/acr.24984","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140067","article-title":"The incidence and predictors of infection in psoriasis and psoriatic arthritis: results from longitudinal observational cohorts","volume":"43","author":"Haddad A","year":"2016","unstructured":"Haddad A, Li S, Thavaneswaran A, Cook RJ, Chandran V, Gladman DD. The incidence and predictors of infection in psoriasis and psoriatic arthritis: results from longitudinal observational cohorts. J Rheumatol. 2016, 43:362-6. 10.3899\/jrheum.140067","journal-title":"J Rheumatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1186\/ar4358","article-title":"Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis","volume":"15","author":"Crnkic Kapetanovic M","year":"2013","unstructured":"Crnkic Kapetanovic M, Saxne T, J\u00f6nsson G, Truedsson L, Geborek P. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther. 2013, 15:R171. 10.1186\/ar4358","journal-title":"Arthritis Res Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/268100-secondary-immunodeficiency-and-vaccine-response-in-rheumatoid-and-psoriatic-arthritis-on-immunosuppressive-medicines","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T11:54:02Z","timestamp":1723031642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/268100-secondary-immunodeficiency-and-vaccine-response-in-rheumatoid-and-psoriatic-arthritis-on-immunosuppressive-medicines"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.66366","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,7]]}}}